The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Phase I study of bb21217 CAR-T therapy in R/R myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares the latest findings from a large Phase I study (NCT03274219) of bb21217, a BCMA-directed CAR T-cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma. Unlike previous BCMA-targeting CAR-T agents, bb21217 is exposed to a PI3K inhibitor during ex vivo culture to enrich the product for a memory-like T-cell phenotype. In total, 72 patients were treated at three dose levels of bb21217, up to the target dose of 450 x 10^6 CAR+ T-cells. The overall response rate across the three groups was 69%. CAR+ T-cells could be detected at 6 months and 12 months in 81% and 60% of patients, respectively. Additionally, a greater number of CD8+ CAR+ T-cells expressing CD27 and CD28 at baseline was associated with a longer duration of response. Overall, these findings support the rationale that enrichment for memory-like T-cells is associated with prolonged efficacy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
